Section of Pharmacology, Pharmacotherapy and Toxicology, Department for Functional Sciences B41, Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium.
Vet J. 2012 Apr;192(1):41-8. doi: 10.1016/j.tvjl.2011.01.020. Epub 2011 Feb 26.
The objective of this study was to investigate whether high-dose inhaled fluticasone propionate (FP), alone or in combination with salmeterol (SAL), is as effective as oral prednisolone in reducing airway inflammation and obstruction in cats with experimentally-induced acute asthma. Six cats sensitised to Ascaris suum (AS) were enrolled in a prospective controlled therapeutic trial and underwent four aerosol challenges, at 1-month intervals with AS allergen. The allergen - stimulated animals received four consecutive days treatment with either oral prednisolone at 1mg/kg twice daily, 500 μg of FP inhaled twice daily, or a combination of FP/SAL at 500 μg/50 μg inhaled twice daily, respectively, according to a randomised cross-over design. Treatment-related changes in lung function, airway responsiveness (AR) and bronchoalveolar lavage fluid (BALF) cytology were assessed. Barometric whole-body plethysmography (BWBP) was used for the assessment of respiratory variables and AR. No significant differences in respiratory rate or Penh (an estimate of airflow limitation measured by BWBP) were detected among treatment groups. Allergen-induced airway hyper-responsiveness was significantly inhibited by all three steroid treatments (P<0.05). The mean BALF eosinophil percentage (±SEM) was lower after oral and inhaled corticosteroid treatment and these changes were significant for groups receiving prednisolone and the FP/SAL combination. Findings suggest high-dose FP, particularly in combination with SAL, is effective in ameliorating airway inflammation and hyper-responsiveness in this model of acute feline asthma, and highlight the potential use of these drugs in cats experiencing acute exacerbations of the naturally occurring disease.
本研究旨在探讨大剂量吸入丙酸氟替卡松（FP），单独或联合沙美特罗（SAL），是否与口服泼尼松龙一样有效，可降低实验性诱导的急性哮喘猫的气道炎症和阻塞。6 只对蛔虫（AS）致敏的猫被纳入一项前瞻性对照治疗试验，并在 1 个月的间隔内接受 4 次 AS 过敏原雾化挑战。在过敏原刺激后，根据随机交叉设计，动物接受连续 4 天的治疗，分别给予口服泼尼松龙 1mg/kg，每日 2 次、500μg FP 每日 2 次吸入或 FP/SAL 500μg/50μg 每日 2 次吸入。评估与治疗相关的肺功能、气道反应性（AR）和支气管肺泡灌洗液（BALF）细胞学变化。使用压力容积全身体积描记术（BWBP）评估呼吸变量和 AR。在治疗组之间，呼吸频率或 Penh（通过 BWBP 测量的气流受限估计值）没有显著差异。所有三种皮质类固醇治疗均显著抑制过敏原诱导的气道高反应性（P<0.05）。口服和吸入皮质类固醇治疗后 BALF 嗜酸性粒细胞百分比（平均值±SEM）降低，泼尼松龙组和 FP/SAL 联合组的变化具有统计学意义。研究结果表明，高剂量 FP，特别是与 SAL 联合使用，可有效改善这种急性猫哮喘模型中的气道炎症和高反应性，并强调这些药物在患有自然发生疾病急性加重的猫中具有潜在用途。
